Tandem Diabetes Care, Inc.

Tandem Diabetes Care, Inc. is an American medical device manufacturer headquartered in San Diego, California, dedicated to improving the lives of individuals with diabetes. The company's core business revolves around developing and commercializing advanced automated insulin delivery systems. Its mission is to create new possibilities for people living with diabetes, their loved ones, and healthcare providers through a user-centric approach, embodying the principle of working "in Tandem" (together) in all aspects of its operations.

Tandem's key product portfolio includes the t:slim X2 insulin pump and the Tandem Mobi system. Both systems are powered by Control-IQ+ advanced hybrid closed-loop technology, which automatically adjusts insulin delivery based on real-time glucose data to help manage blood sugar levels. The t:slim X2 was notable as the first touch-screen insulin pump, while the Tandem Mobi is designed to be the world's smallest durable automated insulin delivery system. Beyond pumps, the company offers essential accessories like infusion sets, remote software updates, and mobile/cloud-based diabetes management applications such as Tandem Source and Sugarmate. Tandem serves patients with both type 1 and type 2 diabetes, primarily marketing its products in the United States, Canada, Switzerland, and the Netherlands, with ongoing international expansion.

John F. Sheridan serves as the President and CEO of Tandem Diabetes Care, a role he assumed in March 2019. In recent news, Tandem Diabetes Care announced in July 2026 the expanded compatibility of its t:slim X2 insulin pump with Abbott's FreeStyle Libre 3 Plus continuous glucose monitoring (CGM) sensor in several international markets, including the UK, Switzerland, Sweden, Finland, and Italy, with further European countries planned for later in the year. The company is positioned as a leading innovator in diabetes technology, emphasizing ease of use and clinical effectiveness in its solutions.